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Background: Malaria in pregnancy (MIP) is a major disease burden in Nigeria and has adverse consequences on
the health of the mother, the foetus and the newborn. Information is required on how to improve its prevention
and treatment from both the providers’ and consumers’ perspectives.
Methods: The study sites were two public and two private hospitals in Enugu, southeast Nigeria. Data was
collected using a pre-tested structured questionnaire. The respondents were healthcare providers (doctors,
pharmacists and nurses) providing ante-natal care (ANC) services. They consisted of 32 respondents from the public
facilities and 20 from the private facilities. The questionnaire elicited information on their: knowledge about malaria,
attitude, chemotherapy and chemoprophylaxis using pyrimethamine, chloroquine proguanil as well as IPTp with
sulphadoxine-pyrimethamine (SP). The data was collected from May to June 2010.
Results: Not many providers recognized maternal and neonatal deaths as potential consequences of MIP. The
public sector providers provided more appropriate treatment for the pregnant women, but the private sector
providers found IPTp more acceptable and provided it more rationally than public sector providers (p< 0.05). It was
found that 50 % of private sector providers and 25 % of public sector providers prescribed chemoprophylaxis using
pyrimethamine, chloroquine and proguanil to pregnant women.
Conclusions: There is sub-optimal level of knowledge about current best practices for treatment and
chemoprophylaxis for MIP especially in the private sector. Also, IPTp was hardly used in the public sector.
Interventions are required to improve providers’ knowledge and practices with regards to management of MIP.
Keywords: Malaria in pregnancy, Chemotherapy, Chemoprophylaxis, IPTp, ProvidersBackground
Pregnant women are very vulnerable and badly affected by
malaria in Africa [1]. In Nigeria, malaria remains a major
public health problem and is responsible for 30 % child-
hood mortality and 11 % of maternal mortality [2-4]. More
than 60 % out-patient visits in Nigeria are due to malaria* Correspondence: onwujekwe@yahoo.co.uk
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distribution, and reproduction in any mediumand it also accounts for 30 % of all hospital admission with
nearly 110million cases and 300,000 deaths per year [3].
Malaria infection during pregnancy has adverse conse-
quences on the health of the mother, the foetus and the
newborn. These effects include spontaneous abortion,
preterm delivery, low birth weight, still-birth, congenital
infection and maternal death [5]. The risk of anaemia in
both the mother and baby is higher in first and second
pregnancies than in later pregnancies [1,6].
During the past decade more effective strategies for pre-
vention and control of malaria in pregnancy (MIP) have
been developed [7]. The control of MIP using drugs couldntral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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through chemoprophylaxis or intermittent preventive
treatment of malaria in pregnancy (IPTp). The current
recommendation to control MIP in areas of stable malaria
transmission relies on prompt and effective case manage-
ment of malaria, the use of intermittent preventive treat-
ment of malaria in pregnancy (IPTp) with at least two
doses of sulphadoxine-pyrimethamine (SP) and the use of
insecticide treated nets (ITNS) [5]. In the context of
chemotherapy, the national treatment guideline recom-
mends the use of quinine in all trimesters and artemether-
lumefantrine in second and third trimesters [2].
Initially, attempts were made to prevent malaria in preg-
nancy using antimalarials which involved regular adminis-
tration of drugs throughout pregnancy in order to sustain
protective blood levels (chemoprophylaxis) [8]. The drugs
used were chloroquine, pyrimethamine and proguanil [9].
However, studies reported the emergence and spread of
drug resistance and adverse outcomes from the drugs [10].
This ultimately led to the concept of IPTp.
Nigeria adopted IPTp as a strategy in 2005 to replace
weekly prophylaxis [11]. IPTp involves the administration
of full curative treatment dose of an effective antimalarial
drug (now only SP) at pre-defined intervals during preg-
nancy. The drug is given irrespective of peripheral blood
malaria parasite status. It is should be provided to all preg-
nant women after 16 weeks of pregnancy [9].
IPTp with SP is offered as a package through focused
ante-natal care (ANC) and as a national protocol, SP is
given free of charge to pregnant women through ANC
services at public health facilities and non-governmental
organisation (NGO) facilities [12]. The treatment doses
are given at least one month apart in the second and
third trimesters [13]. To ensure that a pregnant woman
receives at least two doses, delivery of IPTp should best
be linked to routine scheduled antenatal visits after
quickening. The effectiveness of SP in improving birth
weight, and reducing prevalence of preterm deliveries
and maternal anaemia was reported in Nigeria [14,15].
However, the IPTp coverage in Nigeria is low [12]. Only
18 % pregnant women received an antimalarial drug for the
prevention of malaria during the pregnancy, 11 % received
at least one dose of SP and 7 % received two or more doses
[12]. Hence, it is important to examine current levels of
provision of IPTp and to understand the underlying reasons
behind levels of provision in both public and private sectors.
The paper assesses the knowledge and attitude of pro-
viders about malaria-in-pregnancy and compares the ex-
tent of provision of chemotherapy and chemoprevention
(including IPTp) in public and private hospitals. It also
examines the level of acceptability and use of IPTp. The
information will be useful for improved delivery of ef-
fective interventions in the treatment and prevention of
malaria in pregnancy using drugs.Methods
The study area was Enugu metropolis (state capital),
Enugu State, south-east Nigeria. The state is made up of
seventeen local government areas (LGAs), five of which
are largely urban. It has a population of about 3,367,837
people and lies in an area of approximately 8721.1sq km
land. The temperature in the state ranges between
22.40 C and 30.80 C and the vegetation is tropical rain
forest with two major seasons namely dry (November to
April) and rainy (May to October). It has an annual rain-
fall of between 1520 mm to 2030 mm. Majority of the
residents are subsistence farmers and petty traders.
The state’s health delivery is through a network of for-
mal and informal private and public health facilities.
Malaria transmission in the area is stable and holoen-
demic. However, there is a higher rate of transmission
during the rainy season. The infant mortality rate is
110/1000 and total fertility rate 5.6 and population
growth rate 2.83 % [16].
Study sites
The study was conducted in two public and two private
hospitals in Enugu metropolis. The hospitals were purpos-
ively selected because they were the two busiest public and
private hospitals and so assured the collection of timely ad-
equate data because of the high number of women that re-
ceive ante-natal services (ANC) there. The two public
hospitals were the University of Nigeria Teaching Hospital
(UNTH) Ituku-Ozalla and the Enugu State University
Teaching Hospital (ESUTH). The private hospitals were the
Mother of Christ Specialist Hospital and Mbanefo Specialist
Hospital.
The University of Nigeria Teaching Hospital is a referral
centre. The Obstetrics and Gynaecology (O&G) clinics in
the hospital run concurrently with the ANC clinic from
Monday to Friday. There are five O&G units and each
comprises about six Consultants, 4 Senior Registrars Med-
ical Officers, 2 Pharmacists and 7 Nurses providing ante-
natal care. The clinic attends to an average of about fifty
antenatal women daily including about fifteen new registra-
tions. The ANC clinics in Enugu State University Teaching
Hospital hold from Mondays to Fridays except on Thurs-
days. The clinics are headed by two consultants assisted by
senior registrars, house officers, a pharmacist and nursing
staff. The clinics admit about twenty newly registered ante-
natal women daily and attend to about sixty old cases on
antenatal days. The Mother of Christ Hospital is a faith
based private/specialist hospital. It is an over 50 bedded
hospital. It’s Obstetrics and Gynaecology unit has two con-
sultants, 6 medical officers, nurses and a pharmacist in as-
sistance. The antenatal clinic days holds on Mondays and
Fridays with an average of seventy women including 20
new registrations seen daily. Finally, Mbanefo Specialist
Hospital is a private hospital. It has two consultants that










Malaria in pregnancy is a
very serious illness
27 (84.4) 20 (100) 3.37 (0.064)
Adverse effects on the women
Tiredness 19 (59.4) 2 (10.0) 12.463 (0.001)
Death of baby 25 (78.1) 9 (45.0) 5.967 (0.02)
Anaemia 28 (87.5) 14 (70.0) 0.156 (0.81)
Death of woman 19 (59.4) 3 (15.0) 9.929 (0.002)
Low birth weight 21 (65.6) 5 (25.0) 8.125 (0.004)
Malaria detection in patients
Physical examination 7 (21.9) 0 (0) 0.037 (0.87)
Symptoms recognition 25 (78.1) 9 (47.4) 5.075 (0.02)
Microscopic examination 21 (65.6) 13 (68.4) 0.042 (0.84)
Rapid diagnostic test 14 (43.8) 3 (15.8) 4.194 (0.04)
Self recognition 4 (12.5) 0 (0) 0.283 (0.67)
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attends to about 50 antenatal women and 10 new registra-
tions on antenatal days.
Data collection
The study population was made up of all healthcare provi-
ders that included doctors, pharmacists and nurses that
were directly involved in provision of ANC services in the
hospitals. The sample size was computed using a power of
80 % and confidence level of 95 % and assuming that a
minimum of 15 % of health workers will be knowledgeable
about IPTp. Epi Info software package was used for calcu-
lating sample size. All the consenting healthcare providers
in the ANC services of each health facility were inter-
viewed using a self-administered structured pre-tested
questionnaire. The interviews were undertaken after
obtaining the informed consent from the providers. The
data was collected from May to July 2010.
The questionnaire was used to elicit information from
the providers on: their facility, individual status, knowledge
about malaria, attitude, practice of chemotherapy as well
as chemoprophylaxis using pyrimethamine, chloroquine
and proguanil and chemoprevention using IPTp.
Ethics approval was obtained from the University of
Nigeria Teaching Hospital Ethics Committee. Each re-
spondent also provided a verbal consent.
Data analysis
The data from the public and private sectors were re-
spectively merged to yield public and private sectors’
databases in Epi Info software package. Hence, data from
UNTH and ESUTH were merged to provide data about
public facilities and data from Mbanefo and Mother of
Christ merged to provide data about private facilities. In
data analysis, tabulations were used to examine the dis-
tribution of the various variables and cross-tabulations
used to compare the variables between public and pri-
vate facilities. The denominator in data analysis was the
total number of providers in the public and private sec-
tors respectively. SPSS and STATA software packages
were used for data analysis. Chi-square statistics and
Fischer’s exact tests were used where appropriate to in-
vestigate existence of statistically significant differences
in variables between public and private sectors. The
levels of statistical significance were examined using chi-
square statistics and the threshold set at the 0.05 level.
Results
Description of the providers and their malaria knowledge
and attitude in public and private facilities
A total of 32 and 20 questionnaires were administered to
providers in the public and private facilities respectively.
Most providers in the public (84.4 %) and private (100 %)
hospitals considered malaria-in-pregnancy (MIP) to be avery serious illness (Table 1). Majority of the respondents
in public (87.5 %) and private (70 %) hospitals recognized
anaemia as an adverse effect of severe malaria. Low birth
weight was recognized by 65.6 % of public providers and
25 % of private providers (p= 0,004) as adverse effects of
MIP. It is worthy of note that only 59.4 % of public provi-
ders and 15 % of private providers stated that MIP could
lead to death of a pregnant woman.
Table 1 also shows how the providers stated that MIP
could be diagnosed. In the public sector, a majority of
the providers (78.1 %) knew that malaria could be diag-
nosed using symptoms as against 47.4 % in the private
sector. However, 65.6 % and 68.4 % of public and private
providers stated that microscopic examination could be
used to diagnose malaria. Also, whilst 43.8 % of public
providers knew that RDTs could be used to diagnose
malaria, the proportion in the private sector was 15.8 %.Attitude of providers regarding malaria-in-pregnancy
(MIP)
Most public and private providers strongly agreed that
MIP was high risk factor and responsible for maternal
and neonatal death, low birth weight and anaemia. How-
ever, whilst 15 (75 %) of private providers strongly agreed
that the incidence of MIP was still on the increase des-
pite interventions and polices, it was only 9 (28.1 %) of
the public providers that strongly agreed with the asser-
tion (p = 0.009). A total of 9 (45 %) of the private provi-
ders believed that daily or weekly chemoprophylaxis was
still in use and very beneficial as against 3 (9.4 %) of the
public providers (p = 0.014).
Table 3 Knowledge of IPTp by providers











3 (9.4) 2 (10.0)
Preventive Strategy
with Quinine
0 (0) 1 (5.0) 2.55 (0.47)
Preventive strategy
with SP






3 (9.4) 4 (20.0)
Knowledge of timing
Strongly agree 15 (46.9) 14 (70.0) 9.32 (0.025)
Agree 13 (40.6) 1 (5.0)
Disagree 1 (3.1) 3 (15.0)
Don’t know 1 (3.1) 1 (5.0)
Benefit of direct observation in IPTp
Strongly agree 10 (31.3) 14 (70.0)
Agree 10 (31.3) 3 (15.0) 9.15 (0.027)
Indifferent 6 (18.8) 0 (0)
Don’t know 6 (18.8) 3 (15.0)
Benefits of Health Education to implement
Strongly agree 25 (78.1) 15 (75.0) 0.02 (0.89)
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providers
It was found that 27 (84.4 %) of the public and 18 (90 %)
private providers used blood tests to confirm the diagnosis
of MIP. This was followed by the use of RDT, which was
used by 7 (21.9 %) and 2 (10 %) of public and private pro-
viders respectively. In the public sector, the most common
drug in general treatment of MIP was ACT 22 (68.8 %),
followed by quinine 16 (50.0 %). Conversely, in the private
sector, the most common drug was SP 14 (70.0 %) fol-
lowed by ACT and quinine 5 (25.0 % respectively). Also, in
treating MIP in the first trimester, 11 (34.5 %) of the public
providers gave quinine while 3 (15.0 %) gave the drug in
the private sector (p= 0.01). Other drugs that were pro-
vided were chloroquine tablet by 7 (21.9 %) by the public
providers and 3 (15 %) by the private providers (p= 0.72);
and SP by 4 (12.5 %) of public providers and 13 (65.0 %) of
private providers (p= 0.001).
Perception and provision of chemoprophylaxis by
providers
Table 2 shows that 35 % of the private providers and
18.8 % of public providers found that weekly chemo-
prophylaxis using pyrimethamine, chloroquine and palu-
drine were still very useful control measures for MIP.
The table also shows that 50 % of the private providers
and 25 % of public providers still used chemoprophy-
laxis. However, there was no statistically significant dif-
ference in the number of women that were provided
with chemoprophylaxis in both sectors (p = 0.058).Agree 6 (18.8) 4 (20.0)
Usefulness of IPTp
Very useful 14 (43.8) 11 (55.0) 1.04 (0.60)
Useful 13 (40.6) 7 (35.0)
Not useful 1 (3.1) 0 (0.0)Knowledge and provision of intermittent-preventive
treatment of malaria in pregnancy
It was found that most of the private and public sector pro-
viders respectively knew about IPTp (Table 3). However,Table 2 Level of providers’ perception and provision of
chemoprophylaxis for malaria in pregnancy






Opinion of usefulness of Daraprim, Chloroquine, Paludrine for
chemoprophylaxis
Very useful 6 (18.8) 7 (35.0)
Useful 15 (46.9) 9 (45.0) 4.44 (0.22)
Not useful 5 (15.6) 0 (0)
Don’t know 6 (18.8) 4 (20.0)








10(31.3) 13 (65.0) 3.597 (0.058)whilst 73.7 % of private sector providers strongly agreed
that IPTp should be given at least twice during the course
of the pregnancy with the first after quickening, the propor-
tion was 50 % in the public sector (p= 0.025). Table 3 also
shows that 73.7 % of private sector providers strongly
agreed that IPTp should be given irrespective of fever pres-
entation as against 63.3 % by public sector providers. More
private providers stated that IPTp was very useful com-
pared to public providers.
Table 4 shows that 100 % of the private providers pre-
scribed IPTp compared to 79.3 % of public sector provi-
ders (p = 0.34). The table also shows that among the
providers in the public facilities 71 % recommended
IPTp from 2nd trimester as against 66.7 % in private sec-
tor. Some providers in both sectors prescribed IPTp in
the first trimester.
Table 4 Patterns of provision of IPTp by providers





Provision of IPTp 23 (79.3) 20 (100) 4.49 (0.34)
Best time for provision of IPTp
1st trimester 6 (19.4) 5 (27.8) 1.72 (0.79)
2nd trimester 22 (71.0) 12 (66.7)
3 rd trimester 1 (3.2) 1 (5.6)
Others 1 (3.2) 0 (0.0)
Provision of direct
observed IPTp





12 (37.5) 16 (80) 8.30 (0.004)
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private sectors was SP by 23 (71.9 %) by the public providers
and 18 (90 %) of the private providers (p=0.68). Artesunate
monotherapy were used by 8 (25.0 %) of the public providers
and none by private providers (p< 0.01). Other drugs that
were prescribed for IPTp were chloroquine tablets by 3
(9.4 %) of the public providers and 2 (10.0 %) of the private
providers (p=0.74); quinine by 2 (6.3 %) of the public provi-
ders and 1 (5.0 %) of the private providers; and ACT by 7
(21.9 %) of the public providers and 2 (10.0 %) of the private
providers (p=0.27).
Discussion
Knowledge of malaria among health providers was high in
both public and private sectors, but the public sector provi-
ders conformed more to the WHO recommendation of
using microscopy and rapid diagnostic tools for confirming
malaria in pregnancy [3,17,18]. More of the public provi-
ders recognized the adverse effect of malaria-in-pregnancy
(MIP), in line with the WHO malaria report. Some of these
effects include severe anaemia, low birth weight, and intra-
uterine growth retardation which invariably could lead to
death of the baby [2].
In the provision of chemotherapy, artemisinin-based
combination therapy (ACT) and quinine were the most
commonly used by the public providers, while SP was most
commonly used in the private sector. In the first trimester,
the drugs of choice for the public sector health providers
were quinine, ACT and Chloroquine while SP, ACT and
Quinine were the drug of choice in the private sector. In
the second trimester, the drugs most commonly used in
the public were ACT and SP while the private used SP and
Quinine. In the third trimester, the drugs of choice were
ACT and SP in both the private and public health facilities.
The fact that SP was commonly used for treatment rather
than prevention by the private providers negates the concept
IPTp, which involves the administration of a full therapeutic
course of an antimalarial to pregnant women at specifiedtimes regardless of whether they are infected or not [9]. The
finding that the drug of choice for treatment of malaria in
the first trimester for the public providers was mainly quin-
ine is in line with 2006 guidelines that regards this drug as a
treatment option in the first trimester [19].
The public providers conformed to the 2010 WHO
recommendation in the provision of chemotherapy in
the second trimester. The use of ACT by majority of the
public health providers is in line with the WHO recom-
mendation. Because of the uncertainties of artemisinin
containing drugs, they may not be used in the manage-
ment of uncomplicated malaria in the first trimester. SP
is not given early because of theoretical concerns over
the association of folate antagonists with neural tube
defects and other congenital abnormalities [20]. In the
second trimester, the commonly used drugs in the public
sector were ACT and SP in line with the WHO
recommendation.
Hence, the practice and provision of chemotherapy by
public sector providers conformed to the WHO guide-
lines for malaria treatment in endemic areas and this
was consistent for the three trimesters. A study in Lagos
state found that 53.7 % of prescriptions contained ACT,
28.4 % contained Chloroquine, 16.8 % contained SP and
0.4 % contained Quinine [21]. The current recommenda-
tion for treating severe malaria in high transmission
areas is quinine or an artemisinin derivative [19,22].
However, it is recommended that more interventions are
required to improve prescribing practices of providers,
so that they will stop prescribing chloroquine and artesu-
nate monotherapy for treatment of MIP.
There was irrational provision of services as the daily
and weekly chemopropylaxis, with pyrimethamine, chloro-
quine and proguanil were still being used. The proportion
of private providers giving weekly prophylaxis was still
very high. It was of interest to find that many providers
(although much more in the private sector) stated that
chemoprophylaxis using pyrimethamine, chloroquine and
proguanil were still very useful in the control of MIP and
these drugs were still being prescribed. However, it is
known that the usefulness of weekly chemoprophylaxis
has been limited because of poor adherence by pregnant
women to a weekly or more frequent drug regimen and
also increasing levels of plasmodium falciparum resistance
to the drugs [23]. A previous study that was undertaken in
2001 in Nigeria showed that 86.8 % out of 91 obstetricians
routinely provided malaria chemoprophylaxis using
chloroquine, pyrimethamine, proguanil, and sulphadoxine-
pyrimethamine either singly or in various combinations to
pregnant women. It could be speculated that the greater
use of the chemoprophylaxis by private providers in this
study could be due to lack of knowledge of their decreas-
ing effectiveness. However, further research, especially
using qualitative methods could be used to understand the
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chemoprohylaxis.
Concerning IPTp, it was reassuring that most of the pro-
viders in both sectors were quite knowledgeable about
IPTp and recognized it as a preventive strategy. The fact
that many providers were aware of the benefits of direct
observation of the consumption of drugs is very important
as many of the women when given the drug to take home
may throw it away. Only 36.8 % of 57 women offered SP
in a facility-based study took the drug [24]. A study in
Korongwe district in Tanzania recommended that clean
water, cups and soapy water be made available at facilities
to further strengthen the direct observation strategy [25].
In a study in Gambia the direct observation of SP on an
average of three occasions increased the compliance [9].
The private providers provided IPTp more to the preg-
nant women compared to the public providers. However,
the timing of IPTp was better in the public sector com-
pared to the private sector. It was found that some provi-
ders prescribed IPTp with SP in the first trimester, with
the attendant risks to the foetus. SP was mostly used for
IPTp although some public sector providers also used
ACT. This is in contrast to a study carried out in UNTH,
Enugu [8] where one tenth of Nigerian obstetricians sur-
veyed did not routinely prescribe IPTp during pregnancy
and majority of them relied on pyrimethamine, chloro-
quine and proguanil either singly or in combination.
The study has some limitations, which may have influ-
enced some of the findings. The limitations include the
purposive sampling and using only four healthcare facil-
ities and the mix of providers in those facilities. It is pos-
sible that inclusion of lower level facilities such as
primary healthcare centres and secondary level public
hospitals would have provided a more holistic picture of
nature of provision of treatment and prevention for MIP.
Also, the non-disaggregation of data by types of provi-
ders (because of the limited sample size), constrained
our understanding of influence of type of providers (doc-
tors, nurses, midwives etc.) on case management and
chemoprevention of MIP. Also, qualitative questions and
open ended questions could have helped to elicit more
information on the subject matter, instead of just close-
ended questions that was used. It is also possible that be-
cause self-administered questionnaires were used, some
respondents could have consulted each other on how
and what to fill in the questionnaire.
Future studies should examine the underlying reasons
between high ANC attendance and low IPTp provision,
as well as why behaviour of public and private providers
(including private providers more positive attitude to
IPTp) different in some cases as was found in this study.
Future studies should also incorporate qualitative re-
search methods, so as to elicit more explanatory infor-
mation concerning the nature of provision of treatmentand prevention for MIP and disaggregate the data by dif-
ferent types of healthcare providers. Future studies could
interviewer-administered questionnaires so that the
biases that may arise from respondents consulting each
other before completing the questionnaire will be
limited.
Conclusions
It is recommended that malaria control programmes
should design and implement focused interventions that
will improve prescribing practices of providers so that
they will stop prescribing chloroquine and artesunate
monotherapy for the treatment of MIP. Also increased
Information Education and Communication (IEC) cam-
paigns targeting consumers and providers as well as in-
novative training by National and State Malaria Control
Programmes could be used to limit the provision of in-
appropriate drugs by providers for MIP. It is also import-
ant that both the public and private sector health
providers should implement the direct observation of
therapy (DOT) when using SP for IPTp. Patients should
be provided with disposable cups at the facilities and
clean water in order to strengthen the DOT strategy.
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